Since metastatic breast cancer remains incurable despite
temporary regression of the disease with endocrine therapy or chemotherapy,
palliation of symptoms and prolongation of high-quality life become the major
therapeutic goals in the treatment of these patients. Combination chemotherapy
used as front-line treatment for metastatic disease usually results in 35% to
75% objective responses. However, the complete response rate is relatively low
(approximately 10%) and the average duration of response only 8 months.
Moreover, when disease progression occurs, a standard second-line combination
chemotherapy produces responses in 20% to 45% of patients, depending on whether
an anthracycline was included in the initial treatment.[2,3]
Docetaxel (Taxotere) is a new semisynthetic taxane with
significant anti-neoplastic activity and manageable toxicity, which consists primarily of
myelosuppression. As front-line monotherapy for metastatic breast cancer, it produced an overall response rate of
59%; as second-line therapy it achieved 46%. Even for patients who relapsed
or progressed after prior anthracycline-based chemotherapy, the objective
response rate was 41%.
In addition, a randomized phase III study evaluated
docetaxel/doxorubicin versus doxorubicin/cyclophosphamide (Cytoxan, Neosar) as
front-line chemotherapy of patients with metastatic breast cancer. The study
demonstrated a significantly higher objective response rate (ORR) with
docetaxel/doxorubicin (ORR = 60%) than with doxorubicin/cyclophosphamide (ORR =
47%; P = .008). Docetaxel has a unique mechanism of action; it disrupts
mitosis, promotes microtubular assembly, and suppresses depolymerization of
microtubular bundles to free tubulin.
Gemcitabine (Gemzar) is a novel
S-phase-specific, fluorine-substituted pyrimidine analog, phosphorylated by
deoxycytidine kinase to the active diphosphate and triphosphate metabolites. Gemcitabine diphosphate inhibits
ribonucleotide reductase, which results in the depletion of the intracellular
deoxycytidine triphosphate pools. Reduced deoxycytidine triphosphate levels
promote the competitive incorporation of gemcitabine triphosphate into DNA,
which results in the inhibition of further DNA synthesis by masked-chain
Gemcitabine has a broad range of activity against various
tumors and an especially favorable toxicity profile of mild myelosuppression
and minimal nonhematologic toxicity. When used as a single agent, response
rates ranged from 25% to 46%, depending on the dose administered and whether
patients had previously received chemotherapy.
The distinct mechanisms of action, different intracellular
targets, and activity of both docetaxel and gemcitabine against various tumors provided the rationale for their combination.
Provided that pharmacologic antagonism does not occur and that clinically
relevant doses of both drugs can be delivered together, the combination offers
the potential for superior antitumor activity compared with the individual
This review presents data from phase I and II studies of the
docetaxel/gemcitabine combination in patients with advanced breast cancer.
Weekly Gemcitabine and
Several phase I studies have evaluated the tolerance of
different schedules of the docetaxel/gemcitabine combination in advanced breast
The first study of the combination by Spiridonidis et al
administered docetaxel at escalated doses (45, 60, 75, and 100 mg/m2) either on
day 1 or day 15 while gemcitabine was given in a fixed dose (800 mg/m2) on days
1, 8, and 15. The cycles were repeated every 4 weeks. In all, 40 patients were
enrolled and 132 chemotherapy cycles were delivered with a mean of three
cycles/patient (range: 1 to 11 cycles).
There were 27 and 13 patients enrolled in the day-1 and day-15
docetaxel schedules, respectively. In the day-15 schedule with docetaxel at dose
levels of 45, 60, and 75 mg/m2, only 6 of the 13 patients were able to receive
all of the planned gemcitabine administrations during the first cycle as per
protocol. Overall, the day-15 dose was omitted in 9 of 35 docetaxel cycles
because of thrombocytopenia and elevated liver enzymes, which occurred during
the first cycle in seven patients. This excessive toxicity resulted in a
decreased dose intensity of the drugs in the day-15 docetaxel schedule compared
with the day-1 schedule, enabling the investigators to prematurely close this
arm of the trial.
Conversely, using the day-1 schedule, docetaxel could be
escalated to the dose of 100 mg/m2, which is the maximum tolerated dose for
single-agent docetaxel.[10,11] In the day-1 docetaxel schedule, the day-8
gemcitabine dose was omitted in 19 cycles because of neutropenia (18 cycles) and
thrombocytopenia (1 cycle). During the day-1 docetaxel schedule, the dose-limiting toxicity was reached at the dose of docetaxel
100 mg/m2 because of two episodes of febrile neutropenia and one of liver
toxicity. Nonhematologic toxicity (asthenia) occurred in 30 patients; it was
graded as moderate to severe in 15 patients. The onset of asthenia was
unpredictable, and its severity did not appear to be cumulative. The fluid
retention syndrome was relatively rare (only three patients presented with
severe pedal edema). Grade 3 liver toxicity and grade 3 mucositis occurred in
two patients each.
Rischin et al conducted a phase I trial evaluating different
doses of gemcitabine (800, 1,000, and 1,200 mg/m2) given on days 1 and 8 in
combination with escalated doses of docetaxel (60, 75, 85, and 100 mg/m2) given
on day 8 in cycles of 21 days. The study enrolled 39 previously treated patients
who received a total of 152 chemotherapy cycles (median: 4 cycles/patient;
range: 1 to 8 cycles).
Dose-limiting toxicity was reached at docetaxel 100 mg/m2 and
gemcitabine 1,200 mg/m2, since three of six enrolled patients developed dose-limiting
toxicity events. One patient each experienced febrile neutropenia plus grade 3
asthenia, febrile neutropenia plus grade 3 mucositis, and febrile neutropenia
plus grade 4 neutropenia lasting more than 7 days plus grade 4 thrombocytopenia.
Neutropenia was the predominant hematologic toxicity, with grade 4 neutropenia
occurring in 64% of patients; febrile neutropenia occurred in nine patients
(seven in the first cycle) who experienced 11 episodes. Grade 4 neutropenia
lasting for more than 7 days occurred in 14 cycles. Grade 3 or 4 nonhematologic
toxicity or thrombocytopenia was infrequent, with only one patient developing grade 4 skin
The recommended doses for further phase II studies were defined
as docetaxel 85 mg/m2 and gemcitabine 1,200
mg/m2 every 21 days. However, at
this recommended level, 4 of 10 patients required treatment delay for a total of
11 out of 30 cycles because of slow neutrophil recovery.
1. Hayes DF, Henderson IC, Shapiro CL: Treatment of metastatic
breast cancer: Present and future prospects. Semin Oncol 22(suppl 5):5-21, 1995.
2. Vogel CL: Current status of salvage chemotherapy for
refractory advanced breast cancer. Oncology 10(suppl 6):7-15, 1996.
3. Rubens RD: Routine management of disseminated disease
(including anti-osteoclastic therapy) in Bonadonna G, Hortobagyi AM (eds):
Textbook of Breast Cancer, p. 169. London, Gianni Murtin Dunitz, 1997.
4. Ravdin PM, Valero V: Review of docetaxel, a highly active new
agent for the treatment of metastatic breast cancer. Semin Oncol 24(suppl
5. Ravdin PM: Docetaxel for the treatment of
anthracycline-resistant breast cancer. Semin Oncol 22(suppl 4):17-21, 1995.
6. Nabholz JM, Falkson G, Campos D, et al: A phase III trial
comparing doxorubicin and docetaxel to doxorubicin and cyclophosphamide as
first-line chemtherapy for MBC (abstract). Proc Am Soc Clin Oncol 18:485, 1999.
7. Eisenhauer EA: Docetaxel: Current status and future
prospects. J Clin Oncol 13:2865-2868, 1995.
8. Guchelaar HJ, Richel DJ, van Knapen A: Clinical,
toxicological, and pharmacological aspects of gemcitabine. Cancer Treat Rev
9. Merriman RL, Hertel L, Schultz RM, et al: Comparison of the
antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft
models. Invest New Drugs 14:243-247, 1996.
10. Poplin EAD, Corbett T, Flaherty L, et al:
Difluorodeoxycytidine (dFdC, gemcitabine): A phase I study. Invest New Drugs
11. Carmichael J, Walling J: Advanced breast cancer: A phase II
trial with gemcitabine. J Clin Oncol 13:2731-2736, 1995.
12. Spiridonidis CH, Laufman LR, Jones J, et al: Phase I study
of docetaxel dose escalation in combination with fixed weekly gemcitabine in
patients with advanced malignancies. J Clin Oncol 16:3866-3873, 1998.
13. Kaye SB: Gemcitabine: Current status of phase I and II
trials. J Clin Oncol 12:1527-1531, 1994.
14. Rischin D, Boyer M, Smith J, et al: A phase I trial of
docetaxel and gemcitabine in patients with advanced cancer. Ann Oncol
15. Eckardt JR, Schmidt AM, Needles BM, et al: A phase I study
of the combination of docetaxel and gemcitabine (abstract). Proc Am Soc Clin
Oncol 17:920, 1998.
16. Rigas JR, Rothenberg ML, Davis TH, et al: Phase I clinical
and pharmacokinetic study of docetaxel in combination with two gemcitabine
infusion schedules (abstract). Proc Am Soc Clin Oncol 18:870, 1999.
17. Zoli W, Ricotti L, Dal Susino M, et al: Docetaxel and
gemcitabine activity in NSCLC cell lines and in primary cultures from human lung
cancer. Br J Cancer 81:609-615, 1999.
18. Denes AE, Needles BM, Schmidt A, et al: A comparison of two
schedules of docetaxel in combination with gemcitabine given every other week
(abstract). Proc Am Soc Clin Oncol 19:828, 2000.
19. Burstein HJ, Manola J, Younger J, et al: Docetaxel
administrered on a weekly basis for metastatic breast cancer. J Clin Oncol
20. Kouroussis Ch, Agelaki S, Mavroudis D, et al: A
dose-escalating study of weekly docetaxel in patients with advanced solid
tumors. Cancer Chemother Pharmacol. In press.
21. Brugnatelli S, Danova M, Tamburo M, et al: Weekly schedule
of gemcitabine plus docetaxel in refractory advanced breast cancer: A
dose-finding study (abstract). Proc Am Soc Clin Oncol 19:6091, 2000.
22. Kouroussis C, Kakolyris S, Stathopoulos G, et al: A phase I
study of weekly docetaxel and gemcitabine in advanced non-small cell lung
cancer. Proceedings of the 9th Conference on Lung Cancer, Tokyo, September 9-15,
2000. Lung Cancer 29(suppl 1):43, 2000.
23. Frasci G, Comella P, D’Aiuto G, et al: Weekly docetaxel
plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: A
parallel dose-finding study. Ann Oncol 11:367-371, 2000.
24. Mavroudis D, Malamos N, Alexopoulos A, et al: Salvage
chemotherapy in anthracycline-preteated patients with docetaxel and gemcitabine: A multicenter phase II trial. Ann Oncol 10:211-215, 1999.
25. Fountzilas G, Nicolaides C, Bafaloukos D, et al: Docetaxel
and gemcitabine in anthracycline-resistant advanced breast cancer: A Hellenic
Cooperative Oncology Group phase II study. Cancer Invest 18:503-509, 2000.
26. Laufman LR, Spiridonidis CH, Carman L, et al: Second-line
chemotherapy with weekly gemcitabine and monthly docetaxel in patients with
metastatic breast cancer (abstract). Proc Am Soc Clin Oncol 19:408, 2000.
27. Valero V, Jones SE, Von Hoff DD, et al: A phase II study of
docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin
Oncol 16:3362-3368, 1998.